Biotech Startups
10,020 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
0 investors
0 investors
0 investors
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Its lead asset is inhaled pirfenidone (Aerodone), a nebulized reformulation designed to deliver effective lung levels while reducing the side effects of oral dosing.
0 investors
0 investors
0 investors
GenoPalate offers genetic nutrition analysis paired with health coaching, giving users personalized dietary recommendations based on their DNA and support to apply those recommendations to daily food choices and routines. It serves individual consumers seeking to align their nutrition with their genetics.
0 investors
0 investors
0 investors
0 investors
Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes, including approaches that reintroduce tumor suppressor genes and stabilize glucose levels. Its therapies have received multiple FDA Fast Track Designations and are being evaluated in clinical trials.
0 investors
GenrAb develops neuroprotective therapies derived from the human immune system to treat neurological diseases including ALS, Parkinson's, Alzheimer's, and Multiple Sclerosis. The company addresses unmet needs in neurodegeneration treatment by harnessing immunological pathways to prevent disease progression.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Gibson Oncology develops innovative therapies for glioblastoma and other brain tumors. The company's leadership team brings extensive expertise in drug discovery and development, with a track record of creating over a billion dollars in new companies and approved cancer treatments.
0 investors
GID BIO develops investigational adipose-derived cell therapies and device platforms aimed at offering physicians and patients alternatives between short-term relief and major surgery. The company operates in the regenerative medicine and medical device space.
0 investors
GigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
0 investors
0 investors
0 investors